Table 2.
Best response between examinations of cancer patients given Di Bella multitherapy
| Trial* | Months between examinations | Partial response | Stable disease | Progressive disease | Died | Treatment discontinued† | Not assessable | Total |
|---|---|---|---|---|---|---|---|---|
| Lymphoma | 1 | 1 | 8 | 17 | 6 | 0 | 0 | 32 |
| Lymphoid leukaemia | 2 | 0 | 8 | 10 | 0 | 4 | 0 | 22 |
| Breast cancer: | ||||||||
| Less severe | 2 | 1 | 4 | 23 | 4 | 1 | 0 | 33 |
| More severe | 2 | 0 | 4 | 14 | 10 | 6 | 0 | 34 |
| Lung cancer: | ||||||||
| Treated | 1 | 0 | 1 | 28 | 29 | 4 | 3 | 65 |
| Untreated | 1 | 0 | 6 | 27 | 13 | 4 | 1 | 51 |
| Colorectal cancer | 2 | 0 | 3 | 21 | 2 | 7 | 1 | 34 |
| Pancreatic cancer | 3 | 1 | 6 | 13 | 8 | 1 | 0 | 29 |
| Head and neck cancer | 2 | 0 | 3 | 19 | 7 | 3 | 0 | 32 |
| Glioblastomas | 3 | 0 | 2 | 14 | 4 | 0 | 0 | 20 |
| Advanced neoplasms | 2 | 0 | 2 | 13 | 14 | 2 | 3 | 34 |
| Total | 3 | 47 | 199 | 97 | 32 | 8 | 386 | |
| % (95% CI) | 0.8 | 12.2 | 51.6 | 25.1 | 8.3 | 2.1 | 100 | |
| (0.2 to 2.25) | (9.1 to 15.9) | (46.4 to 56.6) | (20.9 to 29.8) | (5.7 to 11.5) | (0.9 to 4.0) |
*
See footnote to table 1.
†
Discontinued for toxicity or other reasons.